B-intervention	0	7	Hormone
I-intervention	8	15	therapy
O	16	19	and
O	20	25	fatal
O	26	32	breast
O	33	39	cancer
O	39	40	.

O	41	46	Among
O	47	57	unanswered
O	58	67	questions
O	68	70	is
O	71	78	whether
O	79	89	menopausal
O	90	93	use
O	94	96	of
O	97	105	estrogen
O	106	113	therapy
O	114	115	(
O	115	117	ET
O	117	118	)
O	119	121	or
O	122	130	estrogen
O	130	131	-
O	131	135	plus
O	135	136	-
O	136	145	progestin
O	146	153	therapy
O	154	155	(
O	155	158	CHT
O	158	159	)
O	160	169	increases
O	170	174	risk
O	175	177	of
O	178	188	developing
O	189	194	fatal
O	195	201	breast
O	202	208	cancer
O	209	210	i
O	210	211	.
O	212	213	e
O	213	214	.
O	214	215	,
O	216	226	developing
O	227	230	and
O	231	236	dying
O	237	239	of
O	240	246	breast
O	247	253	cancer
O	253	254	.

O	255	260	Using
O	261	262	a
O	263	273	population
O	273	274	-
O	274	279	based
O	280	284	case
O	284	285	-
O	285	292	control
O	293	299	design
O	299	300	,
O	301	303	we
O	304	313	estimated
O	314	323	incidence
O	324	328	rate
O	329	335	ratios
O	336	338	of
O	339	344	fatal
O	345	351	breast
O	352	358	cancer
O	359	361	in
B-eligibility	362	376	postmenopausal
I-eligibility	377	384	hormone
I-eligibility	385	392	therapy
I-eligibility	393	394	(
I-eligibility	394	396	HT
I-eligibility	396	397	)
I-eligibility	398	403	users
O	404	412	compared
O	413	415	to
O	416	419	non
O	419	420	-
O	420	425	users
O	426	428	by
O	429	433	type
O	433	434	,
O	435	443	duration
O	443	444	,
O	445	448	and
O	449	456	recency
O	457	459	of
O	460	462	HT
O	463	466	use
O	466	467	.

O	468	470	HT
O	471	474	use
O	475	480	prior
O	481	483	to
O	484	490	breast
O	491	497	cancer
O	498	507	diagnosis
O	508	510	in
B-intervention-participants	511	514	278
O	515	520	women
O	521	524	who
O	525	529	died
O	530	532	of
O	533	539	breast
O	540	546	cancer
O	547	553	within
O	554	555	6
O	556	561	years
O	562	564	of
O	565	574	diagnosis
O	575	576	(
O	576	581	cases
O	581	582	)
O	583	586	was
O	587	595	compared
O	596	600	with
O	601	604	use
O	605	607	in
B-control-participants	608	612	2224
B-control	613	621	controls
O	622	627	never
O	628	637	diagnosed
O	638	642	with
O	643	649	breast
O	650	656	cancer
O	657	662	using
O	663	674	conditional
O	675	683	logistic
O	684	694	regression
O	694	695	.

O	696	704	Measures
O	705	710	taken
O	711	713	to
O	714	721	address
O	722	731	potential
O	732	736	bias
O	737	740	and
O	741	752	confounding
O	753	761	inherent
O	762	764	in
O	765	769	case
O	769	770	-
O	770	777	control
O	778	785	studies
O	786	794	included
O	795	805	collecting
O	806	809	and
O	810	819	adjusting
O	820	823	for
O	824	832	detailed
O	833	837	data
O	838	840	on
O	841	852	demographic
O	853	856	and
O	857	862	other
O	863	870	factors
O	871	882	potentially
O	883	893	associated
O	894	898	both
O	899	903	with
O	904	906	HT
O	907	910	use
O	911	914	and
O	915	921	breast
O	922	928	cancer
O	928	929	.

B-iv-bin-percent	930	935	Fifty
I-iv-bin-percent	935	936	-
I-iv-bin-percent	936	939	six
I-iv-bin-percent	940	943	per
I-iv-bin-percent	944	948	cent
O	949	951	of
O	952	957	cases
O	958	961	and
B-cv-bin-percent	962	964	68
I-cv-bin-percent	964	965	%
O	966	968	of
O	969	977	controls
O	978	986	reported
B-outcome	987	989	HT
I-outcome	990	993	use
O	993	994	.

O	995	1000	Among
O	1001	1008	current
O	1009	1010	3
O	1010	1011	+
O	1012	1016	year
O	1017	1019	HT
O	1020	1025	users
O	1025	1026	,
O	1027	1031	odds
O	1032	1038	ratios
O	1039	1042	and
O	1043	1045	95
O	1045	1046	%
O	1047	1057	confidence
O	1058	1067	intervals
O	1068	1071	for
B-outcome	1072	1077	death
O	1078	1082	were
O	1083	1084	0
O	1084	1085	.
O	1085	1087	83
O	1088	1089	(
O	1089	1090	0
O	1090	1091	.
O	1091	1093	50
O	1093	1094	,
O	1095	1096	1
O	1096	1097	.
O	1097	1099	38
O	1099	1100	)
O	1101	1104	and
O	1105	1106	0
O	1106	1107	.
O	1107	1109	69
O	1110	1111	(
O	1111	1112	0
O	1112	1113	.
O	1113	1115	44
O	1115	1116	,
O	1117	1118	1
O	1118	1119	.
O	1119	1121	09
O	1121	1122	)
O	1122	1123	,
O	1124	1136	respectively
O	1136	1137	,
O	1138	1141	for
O	1142	1151	exclusive
O	1152	1155	use
O	1156	1158	of
O	1159	1162	CHT
O	1163	1165	or
O	1166	1168	of
O	1169	1171	ET
O	1171	1172	,
O	1173	1176	and
O	1177	1181	were
O	1182	1183	0
O	1183	1184	.
O	1184	1186	94
O	1187	1188	(
O	1188	1189	0
O	1189	1190	.
O	1190	1192	59
O	1192	1193	,
O	1194	1195	1
O	1195	1196	.
O	1196	1198	48
O	1198	1199	)
O	1200	1203	and
O	1204	1205	0
O	1205	1206	.
O	1206	1208	70
O	1209	1210	(
O	1210	1211	0
O	1211	1212	.
O	1212	1214	45
O	1214	1215	,
O	1216	1217	1
O	1217	1218	.
O	1218	1220	07
O	1220	1221	)
O	1222	1225	for
O	1226	1229	any
O	1230	1233	use
O	1234	1236	of
O	1237	1240	CHT
O	1241	1243	or
O	1244	1246	of
O	1247	1249	ET
O	1250	1260	regardless
O	1261	1263	of
O	1264	1269	other
O	1270	1277	hormone
O	1278	1281	use
O	1281	1282	.

O	1283	1288	Point
O	1289	1298	estimates
O	1299	1306	suggest
O	1307	1309	no
O	1310	1319	increased
O	1320	1324	risk
O	1325	1327	of
O	1328	1333	fatal
O	1334	1340	breast
O	1341	1347	cancer
O	1348	1352	with
O	1353	1355	HT
O	1356	1359	use
O	1359	1360	,
O	1361	1369	although
O	1370	1372	50
O	1372	1373	%
O	1374	1383	increases
O	1384	1386	in
O	1387	1391	risk
O	1392	1394	in
O	1395	1401	longer
O	1401	1402	-
O	1402	1406	term
O	1407	1414	current
O	1415	1418	CHT
O	1419	1424	users
O	1425	1431	cannot
O	1432	1434	be
O	1435	1440	ruled
O	1441	1444	out
O	1444	1445	.
